• Minimum of 24 credits of coursework including elective courses, but excluding 1 credit for seminar.
• Participate in weekly seminar each semester. Students in their 3^rd year have the opportunity to give a seminar each year. The final defense fulfills this requirement in the last year of study
• Research credit (i.e. lab rotation) or dissertation credit of at least 3 hours per semester
• Doctoral written and oral exam. The Qualifying Exam process (i.e, written and oral exam) is designed to assess the extent of the student’s knowledge acquired from course work in pharmaceutical science and test his or her ability to integrate and apply knowledge  to practical problems.
• Dissertation and final defense

* Students must register for seminar every semester in which they are in residence

** A minimum of 6 credit hours required for graduation; must be registered for at least 3 credit hours in the semester in which the final defense is conducted

Students are also required to take at least 9 credits of elective courses

Math Electives

• BMME 515 Biomathematical Modeling
• BMME 530 Digital Signal Processing I
• BMME 775 Image Processing and Analysis
• BMME 730 Digital Signal Processing II
• BMME 860 Numerical Methods for Biomedical Engineering
• MATH 528 Mathematical Methods for the Physical Sciences
• MATH 535 Introduction to Probability
• MATH 547 Linear Algebra for Applications
• MATH 564 Math Modeling
• MATH 566 Introduction to Numerical Analysis
• MATH 577 Linear Algebra
• MATH 661 Scientific Computation
• MATH 768 Mathematical Modeling I

Engineering Electives

• BMME 890 Bio Transport    3 credits
• BMME 465 Biomedical Instrumentation I
• BMME 532 Microelectrode Techniques
• BMME 530 Digital Signal Processing
• COMP 665 Images, Graphics and Vision
• BMME 550 Medical Imaging: Ultrasound, MRI and Optical
• BMME 560 Medical Imaging: X-ray, CT and Nuclear
• BMME 551 Medical Device Design
• BMME 580 Microcontroller Applications I
• BMME 515 Introduction to Systems Biology
• BMME 510 Biomaterials
• BMME 505 Biomechanics
• GNET 711-717 (3 x 1 credit) Bioinformatics

Suggested Electives

• BIOC 643 Cell Structure, Function, and Growth Control I (2).  Fall.
• BIOC 644 Cell Structure, Function, and Growth Control II (2) Spring.
• BIOC 651 Macromolecular Equilibria: Conformation Change and Binding(1). Fall.
• BMME 890 Biotechnology (3)
• BMME 515 Introduction to Systems Biology (3)
• BMME 510 Biomaterials (3)
• BMME 790 Graduate Systems Physiology (3 )
• CHEM 430 Introduction to Biological Chemistry (3). Fall and Spring.
• CHEM 431 Macromolecular Structure and Metabolism (3). Spring.
• CHEM 432 Metabolic Chemistry and Cellular Regulatory Networks  (3). . Fall.
• CHEM 466 Advanced Organic Chemistry I (3).  Fall.
• CHEM 467 Advanced Organic Chemistry II (2).  Spring.
• CHEM 480 Introduction to Biophysical Chemistry (3). Fall.
• CHEM 481 Physical Chemistry I (3).  Fall and Spring.
• PHCO701 Introduction to Molecular Pharmacology (2).  Fall.
• PHCO702  Principles  of  Pharmacology  and  Physiology  (3). Spring.
• MCRO614 Immunobiology (3) Fall.
• NC State BEC 475 Global Regulatory Affairs for Medical Products (online)
• NC State BEC 462/BEC 562/CHE 462 Fundamentals of Bio-Nanotechnology=

Other courses can fulfill these electives upon petition by the student and approval by the director of graduate studies or the student’s Ph.D. advisory committee.

Excluding research and seminar credits but including credits from elective courses, students must take a minimum of 24 credits of course work prior to sitting for the Qualifying Exam. Students who have taken relevant coursework prior to enrollment in the Division of Pharmacoengineering and Molecular Pharmaceutics Graduate Program may use that coursework to satisfy graduate course requirements provided that the courses were taken within 8 years of entry into the graduate program and that passing scores (H, P, or A, B) were received. Courses taken more than 8 years previously may be waived on a case-by-case basis (particularly if the individual has been using the relevant skills frequently) at the discretion of the research advisor and with the approval of the division faculty. All requests for waivers of required courses should be submitted in writing to the division director of graduate studies for review by the division faculty. Note that while a student may waive a particular required course, he or she must still complete a minimum of 24 credits of course work.

This DPMP Ph.D. in Pharmaceutical Sciences track has an emphasis in pharmacoengineering, an emerging discipline that integrates engineering methods with pharmaceutical sciences. Pharmacoengineers apply the latest experimental approaches from life sciences, chemistry, and physics in conjunction with theoretical and quantitative methods from engineering, mathematics, and computer science to solve problems in medicine and drug therapies.

We believe in the importance of in-depth training of students both in pharmaceutical sciences and modern engineering, mathematics, and computer science, as well as in the conduct of original research leading to the doctoral dissertation. Thus, we have designed the curriculum to offer rigorous and comprehensive training in the key principles of pharmaceutical sciences and engineering yet maintain a high degree of flexibility for students to tailor the coursework to their specific interests suitable to their research projects.

The program is among the first of its kind in the country and is a joint effort between the UNC Eshelman School of Pharmacy’s Division of Pharmacoengineering and Molecular Pharmaceutics and the Joint Department of Biomedical Engineering at UNC-Chapel Hill and North Carolina State University.

Students work at the interface of engineering and pharmaceutical sciences to develop safer and more effective medicine and medical technologies. It provides students not only with a strong knowledge base in both pharmaceutical sciences and engineering, but also a highly interdisciplinary research experience. Students have the flexibility to work with any of more than two dozen outstanding faculty members with expertise in a variety of fields within pharmacy and engineering.

Math/Applied Math Electives

Engineering Electives

Other courses can fulfill these electives upon petition by the student and approval by the director of graduate studies or the student’s Ph.D. advisory committee.

DPMP Primary Faculty

Kristy Ainslie

(919) 962-4556

ainsliek@email.unc.edu

Kristy Ainslie, Ph.D. applies her knowledge base in biomaterials, and immunology to develop new immune-modulatory therapies that treat and prevent infectious, and autoimmune diseases. Her lab aims to design practical and innovative formulations, taking into account the scalable production and applications in developing nations.

Aaron Anselmo

(919) 966-1126

aanselmo@email.unc.edu

The Anselmo lab focuses on understanding microbe-material-host tissue interactions to develop: (i) formulations for the improved delivery of therapeutic microbes, (ii) materials-based in vitro culture approaches to enable the co-culture of microbial ecologies alongside mammalian cells, and (iii) targeted approaches for the delivery of therapeutic microbes.

Jessica Greene

(919) 445-0150

greenej@email.unc.edu

Jessica Greene, Pharm.D. is an assistant professor in the Division of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy.

Shawn D Hingtgen

(919) 537-3827

hingtgen@email.unc.edu

Due to their expansive utility, stem cell-based therapies hold the potential to redefine therapeutic approaches and provide cures for many terminal diseases. In the Hingtgen lab, we seek to harness the potential of stem cells to develop new and better methods for treating terminal cancers, including brain cancer. We use an integrative approach that begins with creating specially designed targeted therapeutic proteins.

Leaf Huang

(919) 843-0736

leafh@email.unc.edu

The Laboratory of Drug Targeting has been working on liposomes and immunoliposomes for drug delivery. Current activities are focused in the development of nonviral vectors for gene (including siRNA) therapy, and receptor mediated drug and vaccine targeting using self-assembled nanoparticles. The technologies are tested for therapy of cancer and liver diseases in animal models.

Michael Jay

(919) 843-3775

mjay@email.unc.edu

Mike Jay, Ph.D., received his B.S. in pharmacy from the State University of New York at Buffalo in 1976 and his Ph.D. in pharmaceutical sciences from the University of Kentucky in 1980. He was an assistant professor of nuclear medicine at the University of Connecticut Health Center from 1980 to 1981 and then returned to the University of Kentucky as an assistant professor of medicinal chemistry in 1981 and rose through the academic ranks. By the end of his twenty-seven years at the University of Kentucky, he was professor of pharmaceutics and professor of radiology.

Alexander V. Kabanov

kabanov@email.unc.edu

Alexander “Sasha” Kabanov, Ph.D., Dr.Sci., is the Mescal Swaim Ferguson Distinguished Professor and director of the Center for Nanotechnology in Drug Delivery at the UNC Eshelman School of Pharmacy and codirector of the Carolina Institute for Nanomedicine at the University of North Carolina at Chapel Hill. Prior to joining UNC-Chapel Hill in July 2012, Kabanov served for nearly eighteen years at the University of Nebraska Medical Center where he was the Parke-Davis Professor of Pharmaceutical Sciences and director of the Center for Drug Delivery and Nanomedicine, which he founded in 2004.

Sam Lai

(919) 966-3024

lai@unc.edu

Sam Lai, Ph.D., was born in Hong Kong and spent his childhood in both Hong Kong and Vancouver. After completing high school at Phillips Academy, Andover, he attended Cornell University and received his BS in chemical and biomolecular engineering in 2003. He then undertook doctoral studies at Johns Hopkins University, receiving his PhD in chemical and biomolecular engineering in 2007. Following a one-year postdoc, he became a research assistant professor at Johns Hopkins in fall 2008 before joining the UNC Eshelman School of Pharmacy in fall 2010.

Juliane Nguyen

(919) 962-4538

julianen@email.unc.edu

Dr. Juliane Nguyen is an Associate Professor in the Division of Pharmacoengineering and Molecular Pharmaceutics. Her translational research program focuses on developing the next generation of safe and effective biotherapeutics for life-threatening diseases such as cancer and myocardial infarction.

Mark Schoenfisch

(919) 843-8714

schoenfisch@unc.edu

In the Schoenfisch Lab, we work at the interface of analytical chemistry, materials science, biomedical engineering, and biology. The types of multi-disciplinary research opportunities that are available include studies of therapeutics to treat various diseases; sensors that function reliably and continuously, real time, to facilitate disease management; microelectrode and microfluidic sensor design and fabrication for clinical, point-of-care, and diagnostic/prognostic applications; and, new macromolecular scaffolds that manipulate biology and physiology.

Philip Smith

(919) 962-0095

pcs@email.unc.edu

Dr. Smith received a B.S. in Pharmacy from the University of Illinois, Chicago Medical Center, and then a Ph.D. in Pharmaceutical Chemistry, with an emphasis in pharmacokinetics, in 1985 from the University of California, San Francisco. After postdoctoral studies at the National Institutes of Health in Bethesda, MD, as a National Research Council Fellow, he joined the faculty of the College of Pharmacy at the University of Texas at Austin.

DPMP Joint Appointments

Paul Dayton

(919) 843-9521

padayton@email.unc.edu

Prior to joining UNC in 2007, Dayton was research faculty at the University of California at Davis. His research interests currently involve applications of ultrasound imaging for assessment of tissue perfusion and monitoring of response to therapy. Other interests include ultrasound-mediated therapeutic approaches.

Zongchao Han

zongchao@med.unc.edu

The Zongchao Han, Ph.D., M.D., laboratory is interested in developing gene therapies for retinal diseases. Han’s lab is particularly interested in understanding the gene expression patterns that are regulated by the cis-regulatory elements. Another interest of the Han laboratory is to produce a multifunctional NP carrier for specific and efficient gene/drug targeting.

Weili Lin

(919) 843-8120

weili_lin@med.unc.edu

DPMP Research Faculty

Eric Michael Bachelder

ebacheld@email.unc.edu

Bachelder focuses on the development of biomaterials for the treatment of diseases associated with the immune system, inlcuding using liposomes, acid sensitive polymers, and tissue engineering scaffolds.

Elena V Batrakova

(919) 537-3712

batrakov@email.unc.edu

The main focus of Batrakova’s research is to develop a CNS delivery system for antioxidants and neuronal growth factors to attenuate neuroinflammation and produce neuroprotection in patients with neurodegenerative disorders, such as Parkinson’s and Alzheimer’s diseases. For this purpose, her group utilizes inflammatory-response cells, macrophages and monocytes that can migrate toward the inflammation site, cross the blood brain barrier, and release the preloaded drugs in the brain.

Juan Li

(919) 962-0223

juanl@email.unc.edu

Jillian Perry

(919) 843-6995

perryjl@email.unc.edu

Marina Sokolsky

(919) 962-4698

msokolsk@email.unc.edu

Sokolsky-Papkov’s current research centers on design of nano-based, sustained release and remote actuated drug delivery systems for treatment and diagnosis of cancer. My research utilizes several platform nanoparticles based technologies (polymeric micelles and nanoparticles, cell derived exosomes and inorganic nanoparticles) and is focused on engineering treatment modalities for two main types of cancer: brain cancer and brain metastases and diagnosis and treatment of post operative residual disease and metastatic spread with emphasis on (1) designing drug loaded nanoparticles which can effectively home to brain cancer in vivo and deliver tumor specific payload to improve treatment efficacy (2) utilize sustained release and nanotechnology approaches to design delivery systems which can improve non invasive diagnosis of primary metastatic spread, treat residual disease and promote post-operative would healing and (3) utilize intrinsic properties of inorganic nanoparticles to design theranostic delivery systems which combine remotely induced drug release and cell apoptosis.

Junjiang Sun

junjiang_sun@med.unc.edu

Bin Xiao

bxiao@email.unc.edu

DPMP Clinical Faculty

Jessica Greene

(919) 445-0150

greenej@email.unc.edu

Jessica Greene, Pharm.D. is an assistant professor in the Division of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy.

DPMP Adjunct Faculty

Rahima Benhabbour

Ronald Brashear

Yevgeny Brudno

Ken Brouwer

Matthew Burke

Ke Cheng

Ramprakash Govindarajan

Zhen Gu

Geoffrey Hird

Kazunori Kataoka

Natalia Klyachko

Qi-Long Lu

Lesley Marson

Alan Parr

Manmohan Singh

Eric Smith

Richard Stack

David A. Zaharoff

DPMP Staff

Janet Cooke

(919) 537-3465

Ning Sun

(919) 962-0146

nsun@email.unc.edu

Graduate Students

• Cole Batty
• Emily Bonacquisti
• Ameya Chaudhari
• Phillip Durham
• Marshall Fritz
• Mairead Heavey
• Dylan Hendy
• Sarah Anne Howard
• Jordan Baer Joiner
• Lauren Kass
• Jasmine King
• Zhongbo Li
• Timothy Little
• Nicole Lukesh
• Breanna Mann
• Sophie Mendell
• Kunyu Qiu
• Jacob Ramsey
• Natalie Smith
• Rebeca Stiepel
• Jessica Tetterton
• Ava Vargason
• Peter Voorhees
• Alex Woodell
• Isabella Young
• Yu Zhang

Postdocs

Zahra Ashrafi

Mohamed Attia

Adam Brown 

Carlos Cruz-Teran 

Lida Ghazanfari 

Duhyeong Hwang 

Liubov Lifshits 

Chaemin Lim 

Kuo-Ching Mei 

Denzel Middleton 

Edikan Ogunnaike

John Roque

Bhawana Shrestha (Suruchi) 

Sean Simpson 

Xiaopei Zhang 

Murali Maruthamuthu